Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

673 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment.
Nowicka M, Hilton LK, Ashton-Key M, Hargreaves CE, Lee C, Foxall R, Carter MJ, Beers SA, Potter KN, Bolen CR, Klein C, Knapp A, Mir F, Rose-Zerilli M, Burton C, Klapper W, Scott DW, Sehn LH, Vitolo U, Martelli M, Trneny M, Rushton CK, Slack GW, Farinha P, Strefford JC, Oestergaard MZ, Morin RD, Cragg MS. Nowicka M, et al. Among authors: knapp a. Blood Adv. 2021 Aug 10;5(15):2945-2957. doi: 10.1182/bloodadvances.2021004770. Blood Adv. 2021. PMID: 34323958 Free PMC article.
End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.
Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trněný M. Kostakoglu L, et al. Among authors: knapp a. Blood Adv. 2021 Mar 9;5(5):1283-1290. doi: 10.1182/bloodadvances.2020002690. Blood Adv. 2021. PMID: 33651099 Free PMC article. Clinical Trial.
Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
Strefford JC, Nowicka M, Hargreaves CE, Burton C, Davies A, Ganderton R, Hiddemann W, Iriyama C, Klapper W, Latham KV, Martelli M, Mir F, Parker H, Potter KN, Rose-Zerilli MJJ, Sehn LH, Trněný M, Vitolo U, Bolen CR, Klein C, Knapp A, Oestergaard MZ, Cragg MS. Strefford JC, et al. Among authors: knapp a. Blood Adv. 2021 Aug 10;5(15):2935-2944. doi: 10.1182/bloodadvances.2020003985. Blood Adv. 2021. PMID: 34323957 Free PMC article.
Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy.
Klanova M, Oestergaard MZ, Trněný M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G. Klanova M, et al. Among authors: knapp a. Clin Cancer Res. 2019 Aug 1;25(15):4634-4643. doi: 10.1158/1078-0432.CCR-18-3270. Epub 2019 May 3. Clin Cancer Res. 2019. PMID: 31053601
Evaluation of the effect of prospective biomarker testing on progression-free survival in diffuse large B-cell lymphoma.
Szafer-Glusman E, Liu J, Sinha A, Peale FV Jr, Ray J, Horn C, Oestergaard MZ, Kornacker M, Sehn LH, Vitolo U, Knapp A, Venstrom J, Byrtek M, Punnoose E. Szafer-Glusman E, et al. Among authors: knapp a. Leuk Lymphoma. 2021 Apr;62(4):999-1002. doi: 10.1080/10428194.2020.1849674. Epub 2020 Dec 16. Leuk Lymphoma. 2021. PMID: 33325309 No abstract available.
Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study.
Kostakoglu L, Mattiello F, Martelli M, Sehn LH, Belada D, Ghiggi C, Chua N, González-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Bolen C, Knapp A, Sellam G, Nielsen T, Sahin D, Vitolo U, Trněný M. Kostakoglu L, et al. Among authors: knapp a. Haematologica. 2022 Jul 1;107(7):1633-1642. doi: 10.3324/haematol.2021.278663. Haematologica. 2022. PMID: 34407602 Free PMC article. Clinical Trial.
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Cheson BD, et al. Among authors: knapp a. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584548 Clinical Trial.
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy.
Mir F, Mattiello F, Grigg A, Herold M, Hiddemann W, Marcus R, Seymour JF, Bolen CR, Knapp A, Nielsen T, Casulo C. Mir F, et al. Among authors: knapp a. Am J Hematol. 2020 Dec;95(12):1503-1510. doi: 10.1002/ajh.25973. Epub 2020 Sep 16. Am J Hematol. 2020. PMID: 32815559 Free PMC article. Clinical Trial.
673 results